|

Liposome-encapsulated Daunorubicin-Cytarabine Clinical Trials

8 actively recruiting trials across 4 locations

▼ -1 trial since June 2026

Also known as: CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection +5 more

Pipeline

Phase 1: 2Phase 2: 4Phase 3: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center3
  • National Cancer Institute (NCI)2
  • Thomas Jefferson University1
  • Ohio State University Comprehensive Cancer Center1
  • Children's Oncology Group1

Indications

  • Cancer8
  • Refractory Acute Myeloid Leukemia4
  • Recurrent Acute Myeloid Leukemia3
  • Acute Myeloid Leukemia3
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells2

Birmingham, Alabama3 trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Hospital of Alabama

Phase 3
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Houston, Texas3 trials

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 2
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M D Anderson Cancer Center

Phase 1
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 2

Sacramento, California1 trial

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

UC Davis Comprehensive Cancer Center

Phase 1/2

Philadelphia, Pennsylvania1 trial

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.